Target Price | JPY624.29 |
Price | JPY740.00 |
Deviation |
15.64%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Sumitomo Dainippon Pharma 2026 .
The average Sumitomo Dainippon Pharma target price is JPY624.29.
This is
15.64%
register free of charge
JPY900.00
21.62%
register free of charge
JPY420.00
43.24%
register free of charge
|
|
A rating was issued by 7 analysts: 1 Analysts recommend Sumitomo Dainippon Pharma to buy, 4 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Sumitomo Dainippon Pharma stock has an average upside potential 2026 of
15.64%
register free of charge
|
Mar '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion JPY | 314.56 | 360.30 |
43.38% | 14.54% | |
EBITDA Margin | 11.54% | 13.11% |
22.16% | 13.64% | |
Net Margin | -100.13% | 4.23% |
646.55% | 104.22% |
7 Analysts have issued a sales forecast Sumitomo Dainippon Pharma 2025 . The average Sumitomo Dainippon Pharma sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Sumitomo Dainippon Pharma EBITDA forecast 2025. The average Sumitomo Dainippon Pharma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Sumitomo Dainippon Pharma Analysts have issued a net profit forecast 2025. The average Sumitomo Dainippon Pharma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Mar '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share JPY | -792.79 | 38.37 |
322.71% | 104.84% | |
P/E | 19.28 | |
EV/Sales | 1.62 |
3 Analysts have issued a Sumitomo Dainippon Pharma forecast for earnings per share. The average Sumitomo Dainippon Pharma <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Sumitomo Dainippon Pharma stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Sumitomo Dainippon Pharma...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.